2017
Overall survival in patients with glioblastoma before and after bevacizumab approval
Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm JH. Overall survival in patients with glioblastoma before and after bevacizumab approval. Current Medical Research And Opinion 2017, 34: 813-820. PMID: 29025274, DOI: 10.1080/03007995.2017.1392294.Peer-Reviewed Original ResearchConceptsOverall survivalTreatment of patientsBevacizumab approvalProgressive glioblastomaGBM diagnosisUS population-based cancer registry dataPopulation-based cancer registry dataCox proportional hazards regressionLarge population-based studyOS of patientsApproval of bevacizumabGross total resectionKaplan-Meier analysisPopulation-based studyProportional hazards regressionLimited therapeutic optionsCancer registry dataAdjusted hazardAdult patientsMedian ageTotal resectionStudy cohortAggressive diseaseHazards regressionTherapeutic options
2011
A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression
Mason WP, Belanger K, Nicholas G, Vallières I, Mathieu D, Kavan P, Desjardins A, Omuro A, Reymond D. A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. Journal Of Neuro-Oncology 2011, 107: 343-349. PMID: 22048878, DOI: 10.1007/s11060-011-0747-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBrain NeoplasmsChromatography, LiquidDibenzazepinesErbB ReceptorsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGlioblastomaHumansInfusions, IntraventricularKaplan-Meier EstimateMagnetic Resonance ImagingMaleMiddle AgedPTEN PhosphohydrolaseTandem Mass SpectrometryConceptsPharmacokinetic evaluationProgressive glioblastomaFirst progressionM2/dayPhase II studyMR scansPhase II trialContinuous intravenous administrationBlood-brain barrierLack of efficacyPeripheral benzodiazepine receptorEvaluable patientsStable diseaseII trialRadiographic progressionAdverse eventsII studyRecurrent glioblastomaDisease progressionDrug levelsIntravenous administrationBiomarker assessmentPatientsAnimal modelsBenzodiazepine receptors